Drug Profile
Safusidenib - AnHeart Therapeutics
Alternative Names: AB-218; DS-1001; DS-1001bLatest Information Update: 13 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; National Cancer Center (Tokyo)
- Developer AnHeart Therapeutics; Daiichi Sankyo Company; National Cancer Center (Tokyo)
- Class Antineoplastics
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioma
- Phase I Cholangiocarcinoma; Solid tumours
- No development reported Acute myeloid leukaemia; Chondrosarcoma
Most Recent Events
- 13 Nov 2023 Daiichi Sankyo Company announces intention to submit regulatory applications for approval for Glioma in some undisclosed countries/regions (Daiichi Sankyo Company pipeline, November 2023)
- 26 May 2023 Phase-II clinical trials in Glioma (Monotherapy, Recurrent, Metastatic disease, Second line therapy or greater) in USA (PO) (NCT05303519)
- 06 May 2023 Phase-I clinical trials in Cholangiocarcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT05814536)